Phase 0 study to assess [111In]-DOTA-h11B6 to target human kallikrein-2 (hk2) in men with metastatic castration-resistant prostate cancer

被引：0
|
作者：
Morris, Michael J.
O'Donoghue, Joseph A.
Chetty, Dushen
Russell, Mike
Zulch, Emma
Avadhani, Anjali Narayan
Divgi, Chaitanya R.
Pandit-Taskar, Neeta
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] J&J, Berwyn, PA USA
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] Columbia Univ, Meadowbrook, Qld, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS249
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
    Matsubara, Nobuaki
    Uemura, Hirotsugu
    Satoh, Takefumi
    Suzuki, Hiroyoshi
    Nishiyama, Tsutomu
    Uemura, Hiroji
    Hashine, Katsuyoshi
    Imanaka, Keiichiro
    Ozono, Seiichiro
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (12) : 1216 - 1226
  • [22] A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
    Emmanuel S. Antonarakis
    Elisabeth I. Heath
    Edwin M. Posadas
    Evan Y. Yu
    Michael R. Harrison
    Justine Y. Bruce
    Steve Y. Cho
    Gregory E. Wilding
    Gerald J. Fetterly
    David G. Hangauer
    Min-Fun R. Kwan
    Lyn M. Dyster
    Michael A. Carducci
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 883 - 892
  • [23] A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
    Antonarakis, Emmanuel S.
    Heath, Elisabeth I.
    Posadas, Edwin M.
    Yu, Evan Y.
    Harrison, Michael R.
    Bruce, Justine Y.
    Cho, Steve Y.
    Wilding, Gregory E.
    Fetterly, Gerald J.
    Hangauer, David G.
    Kwan, Min-Fun R.
    Dyster, Lyn M.
    Carducci, Michael A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 883 - 892
  • [24] Final analysis of the phase 1b/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent.
    Markowski, Mark Christopher
    Eisenberger, Mario A.
    Pieczonka, Christopher Michael
    Getzenberg, Robert H.
    Rodriguez, Domingo
    Barnette, K. Gary
    Steiner, Mitchell S.
    Saltzstein, Daniel R.
    Antonarakis, Emmanuel S.
    Tutrone, Ronald F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment
    Madan, Ravi A.
    Schmidt, Keith T.
    Karzai, Fatima
    Peer, Cody J.
    Cordes, Lisa M.
    Chau, Cindy H.
    Steinberg, Seth M.
    Owens, Helen
    Eisner, Joel
    Moore, William R.
    Dahut, William L.
    Gulley, James L.
    Figg, William D.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (04) : 258 - +
  • [26] In vivo evaluation of 177Lu-labeled h11B6, a humanized antibody for hK2 targeting in prostate cancer
    Timmermand, Oskar Vilhelmsson
    Larsson, Erik
    Strand, Sven-Erik
    Thuy Tran
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [27] A Trial Postmortem: Challenges in Conducting a Randomized, Double-blind, Phase 2 Study in Men with Castration-resistant Prostate Cancer
    Geynisman, Daniel M.
    Szmulewitz, Russell Z.
    Stadler, Walter M.
    EUROPEAN UROLOGY, 2012, 62 (05) : 864 - 866
  • [28] A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress
    Jani, Chinmay
    Xie, Wanling
    Ajmera, Archana
    Araneta, Arlene
    Jamieson, Christina
    Folefac, Edmund
    Hussain, Arif
    Kyriakopoulos, Christos
    Olson, Adam C.
    Parikh, Mamta
    Parikh, Rahul Atul
    Saraiya, Biren
    Jabbour, Salma K.
    Ivy, S. Percy
    Van Allen, Eliezer Mendel
    Lindeman, Neal Ian
    Kochupurakkal, Bose
    Shapiro, Geoffrey
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] A phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE): Results of the phase 1 study.
    McKay, Rana R.
    Xie, Wanling
    Ajmera, Archana
    Saraiya, Biren
    Parikh, Mamta
    Folefac, Edmund
    Olson, Adam C.
    Choudhury, Atish Dipankar
    Einstein, David Johnson
    Heath, Elisabeth I.
    Parikh, Rahul Atul
    Kunos, Charles
    Ivy, S. Percy
    Shapiro, Geoffrey
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
    Kenneth J. Pienta
    Jean-Pascal Machiels
    Dirk Schrijvers
    Boris Alekseev
    Mikhail Shkolnik
    Simon J. Crabb
    Susan Li
    Shobha Seetharam
    Thomas A. Puchalski
    Chris Takimoto
    Yusri Elsayed
    Fitzroy Dawkins
    Johann S. de Bono
    Investigational New Drugs, 2013, 31 : 760 - 768
12345